Oral therapies for human microbiome modulation
Vedanta Biosciences is creating a new class of drugs to modulate the human microbiome. The foundation invested in the company to develop new interventions and therapeutics based on bacterial consortia for the treatment of enteric disease and childhood stunting in the developing world.
- Focus areas
- Agriculture & Nutrition
- Investment type
- Direct equity
- Status
- Active
- Initial investment
- Series C-2
- Partnered in
- 2018
- Headquarters
- USA
More about our work
Our focus
We embrace science and technology innovations that solve old problems in new ways, challenge status quos, and build on past breakthroughs. Our six domains of focus comprise 40+ program strategies across the foundation’s nearly $9B annual charitable support.
Investment Approach
How the Strategic Investment Fund is fostering partnerships with the private sector to leverage the globe’s most groundbreaking global innovations for societal good.
Our Team
The SIF Investment Committee brings depth of experience to global investment programs, with a proven track record of innovation across sectors and scale.